Fifteen ER nurses leave Ontario hospital over overcrowding, safety issues, union says - The Globe and Mail

Major tobacco-tax reforms in several emerging economies have sharply increased cigarette prices and helped drive down smoking, offering powerful lessons for countries seeking to protect health, raise revenue and advance the World Health Organization’s 3 by 35 Initiative. A new independent analysis of 15 countries finds that every country made improvements to cigarette taxation between 2009 and 2025. The strongest results came where governments acted boldly, substantially raising taxes, simplifying tax systems and preventing cigarettes from becoming more affordable as incomes rose. WHO urges countries to use health taxes to increase the real prices of tobacco, alcohol and sugary drinks by 2035. The 3 by 35 Initiative aims to reduce consumption of products that drive noncommunicable diseases and injuries, while generating resources that governments can invest in health and development. “The evidence is clear: when governments make harmful products significantly more expensive, people consume less, lives are saved and public revenues rise,” said Dr Etienne Krug, Director, Department of Health Determinants, Promotion and Prevention, WHO.

Bioengineer.org news storyFor millions of people living with HIV, antiretroviral therapy has transformed a once-fatal infection into a manageable chronic condition. Yet the very drugs that suppress the virus can carry quiet costs, and one of the most insidious is bone loss. Tenofovir disoproxil fumarate, or TDF, has been a cornerstone of HIV treatment worldwide for two decades, prized for its potency, durability, and low cost. But a growing body of evidence has linked TDF exposure to measurable reductions in bone mineral density, raising an increasingly urgent clinical question: once bone has been lost on a TDF-based regimen, can it be recovered? A new prospective cohort study, published in BMC Infectious Diseases, offers some of the most detailed longitudinal evidence to date that the answer, for many patients, is yes. The research team enrolled 223 virologically suppressed men living with HIV who had low bone mineral density while taking TDF-based antiretroviral therapy.

The new treatment kills off a sub-group of fat cells. (Jian Fan/iStockphoto/Getty Images) Early clinical trials into a new fat reduction treatment have reported promising results, and the treatment takes a more unusual approach: Rather than shrinking fat cells, as most weight loss strategies do, it safely and naturally kills them off. The drug here is CBL-514, which is administered via injection. As well as proving effective at reducing subcutaneous fat (just below the skin), there's evidence it can also reduce visceral fat (stored deeper around the organs). According to the team behind the trials, CBL-514 and its unconventional strategy have the potential to reduce fat in key areas of the body – with further benefits that come with weight loss likely to follow. "We expect that patients will be pleased by the cosmetic effects, such as the flatter stomach that can come with subcutaneous fat loss," says endocrinologist Timothy Garvey, from the University of Alabama at Birmingham, who headed up the trial.